Press Releases 2015

2015 | 2014 | 2013 | 2012
January 23, 2015Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 23, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it has earned a $25 million milestone payment from Novartis. This payment was triggered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopting a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyu... 
Printer Friendly Version
January 09, 2015Incyte Board Appoints Two New Directors
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 9, 2015-- Incyte Corporation (Nasdaq: INCY) today announced the appointment of Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin Pharmaceutical Inc., and Paul J. Clancy, Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc., as new Directors. The appointments are effective January 20, 2015. “The Incyte board welcomes Jean-Jacques and Paul as their extensive and re... 
Printer Friendly Version
January 09, 2015Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3 Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies Agenus to receive $60 million comprised of a $25 million technology and program access fee under the collaboration plus $35 million equity investment in Agenus at $4.51/share Agenus eligible to receive up to $350 million in development, regulatory and commercial... 
Printer Friendly Version